Oxaliplatin is generally preferred over cisplatin due to its lower toxicity and comparable effectiveness.93 Docetaxel-based triplet chemotherapies showed higher response rates and longer progression-free survival, but these advantages are associated with increased toxicity.96 Results from the phase III GASTFOX-PRODIGE 51 study evaluated adding docetaxel to FOLFOX in the first-line treatment of HER2-negative, advanced gastric or GEJ adenocarcinoma. Here, ERBB2 is linked to gastroesophageal junction adenocarcinoma.